Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Drugs for Orthopedics/Orthopedic Surgery in Phase II Clinical Development

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Bone Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Catalent Pharma Completes Acquisition of Bone Therapeutics’ Cell Therapy Manufacturing Subsidiary Skeletal Cell Therapy Support

              Contact the Supplier

              Lead Product(s): ALLOB

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Catalent Pharma Solutions

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition November 16, 2020

              Details:

              Catalent has purchased the shares of SCTS and a purpose-built CGxP facility of approximately 41,000 square-foot. Catalent will undertake the manufacturing of clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product.

              Bone Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Bone Therapeutics, Catalent Ink Pact to Streamline Production of Allogeneic Cell Therapy Product, ALLOB

              Contact the Supplier

              Lead Product(s): ALLOB

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Catalent Pharma Solutions

              Deal Size: $14.2 million Upfront Cash: Undisclosed

              Deal Type: Acquisition October 30, 2020

              Details:

              Agreements will streamline and economize the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic cell therapy product and will enable Bone Therapeutics to focus on the development of products from its differentiated MSC platform of cell and gene therapy.

              Bone Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Bone Therapeutics’ Allogeneic Cell Therapy Product, Allob, Shows 90% Fusion Rate at 24 Months in Phase II A Studyinn Lumbar Spinal Fusion

              Contact the Supplier

              Lead Product(s): ALLOB

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 14, 2020

              Details:

              The 24 month follow-up data of this Phase IIa clinical trial have shown that patients treated with ALLOB in spinal fusion procedure show a high incidence in fusion, and benefit from a sustained, clinically meaningful improvement in function and pain throughout the 24 months.

              Heron Therapeutics